Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with
severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to
omalizumab over time will be assessed by physicians and patients evaluating the overall
improvement in control of their asthma.
THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.